EP0874990A1

EP0874990A1 - Storage-stable particle, in particular carrier for carrier-bound reactions, and methods of producing said particle

Info

Publication number: EP0874990A1
Application number: EP96939898A
Authority: EP
Inventors: Dmitri Plaksine; Elena Gromakovskaia; Christoph ABION Beteiligungs ERHARDT
Original assignee: Abion Beteiligungs und Verwaltungs GmbH
Current assignee: Abion Beteiligungs und Verwaltungs GmbH
Priority date: 1995-11-22
Filing date: 1996-11-22
Publication date: 1998-11-04
Also published as: MX9804040A; JP2000500798A; IN182876B; WO1997019354A1; DE19680980D2; BR9611611A; US20020071908A1; AU7696696A; US6444261B1; CN1207810A

Abstract

The proposed storage-stable particle comprises at least one first and at least one second component. The second component, consisting of at least one cross-linkable polymer, forms at least a partial cladding and/or coating around the first component (core). The first component has at least one measurable characteristic which can be produced by reaction between the first component and the cross-linkable polymer and subsequent reaction between the products of that first reaction with a cross-linking agent, so that the first component remains in storage-stable form in the second component.

Description

Particle that is stable on storage, in particular carrier for carrier-bound reactions and method for its production

The present invention relates to a storage-stable particle, in particular a particulate carrier for carrier-bound reactions, detection and / or isolation methods, a process for the production of this storage-stable particle and uses of the particle according to the invention

Particulate carriers, consisting of a solid none and a polymer, are known per se and have already been used for many purposes. In particular, such particles have been used for markers for immunoassays in order to connect a solid core to an affection component via polymers, for example biopolymers In particular, brine of metal particles, for example magnetic iron particles or colored gold particles, non-metal particles, for example selenium, coal dust, SiO ₂ or ceramic particles, blood cells or even latex particles of another polymer with different (binding) properties were used as the particulate material

No. 4,230,685 describes an improvement in the attachment of specific binders to magnetic particles, wherein a particle is coated with an acrylate polymer or a polysaccharide, protein A being bound to this coating by means of glutaraldehyde

No. 4,452,773 describes the production of magnetic iron-dextran microparticles. These particles have a size of 100 to 700 Å, in particular 300 to 400 Å. Many of the particles are colloidal and ferromagnetic with one. Dextran shell The particles obtained are functionalized by periodate oxidation

EP-B-452 342 relates to super-paramagnetic particles coated with polysaccharides, colloidal particles. The particles can be connected to other groups. By sorting out the particle mixture into sub-fractions which have uniform magnetization, compositions are obtained which have homogeneous properties with regard to their retardation in have a magnetic field The possibility of separation according to Gioße is mentioned. Preferred are coatings of polysaccharides or proteins. Polysaccharides are functionalized by peilodate oxidation. Functionalization with cyanogen bromide is also possible. The piotein shell can be bound to certain molecules via side-chain amino groups or sul fhydiyl groups take place

DE-A-40 37 724 relates to devices for immunoassays in which direct or indirect markers are used. Direct markers are preferred since they do not require any additional steps to make test results visible. Examples of direct markers are metal sols, dye sols, latex particles and color indicators , colored substances, which are located in liposomes, and non-metal sols such as a carbon sol. In a further aspect, DE-A-40 37 724 relates to an immunochemically active marker. A coal dust particle is adsorptively bound to a ligand or a ligand conjugate. The sensitivity of the test becomes Eg for human chorionic gonadotropic hCG with 25 mlU / ml (IU = international units) specified

EP-A-0 410 893 describes a method for determining and recognizing an antibody in biological fluids which is directed against a specific antigen. The insoluble carrier particles mentioned are composed of cells, gelatin particles, microcapsules, organic polyme, anoiganic fine particles or colloidal of Metal or metal compounds that are finely dispersed with bovine serum albumin or cholesterol.

EP-A-0 032 270 also describes a quantitative and / or qualitative determination of an immunological component, in which one or more labeled compounds are used, which by direct or indirect coupling of such a component or components to particles from an aqueous dispersion ¬ sion of a hydrophobic dye or pigment or polymeric cores, which smd coated with such dyes or pigments, is or will be obtained.

EP-A-0 321 008 relates to a method for determining one or more components of a reaction between a specifically binding protein and the corresponding bindable substance in a sample, the mutual activity of such components and at least one labeled component being obtained by coupling or adsorption of sol particles of the label directly or indirectly onto the component. Before ^¬ ferred sol particles smd phosphorus, carbon and / or silicon. Agglutination and aggregation can be prevented by coating the particles with macromolecules which contain polar groups, such as proteins, polyethylene glycols, polymeric carbohydrates, polyhydric alcohols and the like. Suitable protection pro- tems are antigens, antibodies and anti-antibodies. Immunochemical inert materials such as albumin, polyethylene glycol or other polar macromolecules can also be used. The test sensitivity is given for example for rabbit immunoglobulin G with 1.5 ng absolute.

EP-A-0 184 710 relates to magnetic microsphere (MIMS), a process for its production from water-in-oil emulsion and its use for the separation and isolation of biological particles, in particular natural or artificial cells. The magnetic microspheres obtained by the process according to the invention are stabilized by crosslinking and carry functional groups on the surface which are the covalent ones Allow binding of biologically active ligands The magnetic microspheres described above consist of a magnetic component which is incorporated in a coagulated matrix protein. The surface of the matrix protein is activated by functional groups for binding biological particles. In particular, the matrix protein is a globular protein such as alumni the matrix protene is preferably activated by aldehyde groups

WO-A-92/08134 relates generally to colloidal particles with a crosslinked coating on which there are functional groups. Magnetic or non-magnetic particles with biodegradable crosslinked gelatin coating smd are preferred, to which biological substances or molecules are covalently bound. These include, in particular, monoclonal ones Anticoipei The monoclonal antibodies, which are bound to the particles in this way, are used in various positive and negative biological assays

EP-A-0 298 368 relates to a method for carrying out a diagnostic immunoassay using colloidal iron-metal-containing particles with conjugates bound to them, which are able to specifically recognize the analyte to be determined. The test sensitivity for hCG is in the mlU / ml - Area

EP-A-0 280 560 discloses Streptococcus A antigen antibodies which have been covalently bound to core / shell polymer particles, the shell made of poly (mp-chloromethylstyrene) and the core made of poly (styrene-co-2-acetoacetoxydethyl methylacrylate) ) was built up containing Oil Red EGN in the core in order to obtain an agglutination reagent

The US-A-4, 452, 886 describes the polymerization of lysine with glutaraldehyde and Congo red to color particles. The test sensitivity for hCG is in the 1000 lU / ml range In his book "Alternative Immunoassays", John Wiley & Sonε, Chicheεtei, New York etc., WP Collms describes the advantages of particle markers in the chapter "Disperse Dye Immunoassay (DIA)" and highlights the importance of essential parameters such as particle size, distribution and shape, solubility in organic solvents, colloid stability and binding capacity, for example for antibodies. The test sensitivities mentioned by him are in the mlU / ml range. The conjugates are stable for at least 15 months if they are lyophilized Store at -20 ° C or 4 ° C, aqueous conjugates should be used within 6 days of preparation

JP-A-0686771 relates to encapsulated toners and their production

The inert cores described in the prior art have significant disadvantages. If the cores are polymerized in, the desired core property is affected very badly. When the polymer is adsorbed onto the core with subsequent covalent or other binding of the affinity component, the binding of the core is usually weak , so that long-term stability is not guaranteed. In addition, the methods according to the prior art only bind one or a few reactive or affmitate components

The technical problem on which the invention is based is to provide stable particles with characteristic properties which can be used, in particular marker properties, to which, if appropriate, many reactive components can also be bound at the same time. The stability should in particular also include long-term storage stability

The problem on which the invention is based is solved by a storage-stable particle, in particular particle-shaped carrier according to the features of claim 1. The subclaims 2 to 18 relate to preferred embodiments of the invention appropriate particle. Claim 19 with the associated subclaims 20 and 22 relates to a method for producing the storage-stable particle according to the invention. Claims 23 to 31 relate to uses of the particle according to the invention.

The storage-stable particle according to the invention is particularly intended for carrier-bound reactions, detection and / or isolation processes. It consists of at least a first and a second component, the particle being suitable for being provided with a reactive component, in particular a specific reactive component. The second component consists of a crosslinkable polymer and virtually forms a shell which at least partially envelops and / or envelops the first component as a core.

The first component has at least one detectable property. Reactive components can be arranged on the second component. The storage-stable particle is characterized by its production process and can be obtained by reacting the first component with the crosslinkable polymer, then reacting the product formed with a crosslinking agent, so that the first component is arranged in the second component in a stable manner. The feature of the storage-stable arrangement of the first component m of the second component means that even in the case of prolonged storage, under possibly unfavorable conditions, the first component remains in the casing. In an embodiment of the method according to the invention, this means, for example, that the first component is an elutable dye, that this dye remains essentially quantitatively in the shell which is formed from the second component. Bleeding of the dye is thus prevented. This means that the sheath, formed from the second component, encloses the first component sufficiently tightly. The condition to be observed according to the invention that the first component can be arranged in the second component in a stable manner is achieved, for example, by that the crosslinking agent is used in a large excess. The crosslinking agents can typically be present in ten times the concentration of the respective reactive group of the second component. The crosslinking agent preferably contains more than 10 to 100 times more reactive groups than corresponding groups of the second component. who react to one another with networking

The reaction conditions are preferably set in such a way that the second component is enveloped or enveloped by the second component

The second component which forms the carrier according to the invention is preferably a polymer which has active or activatable functional groups which can react with the crosslinking agent or with the reactive components, or both, since the second component of the polymer according to the invention can form the carrier The polymer can also be formed from proteins and / or polyamides with functional groups. Basically, other polymers such as biopolymers or monomers are also conceivable, as long as crosslinking is possible second component can be networked with at least bifunctional connections

Polymers are preferably used which adsorptively stabilize the aqueous suspension of component 1, in particular polar polymers

The reactive components arranged on the second component of the particle according to the invention are, in particular, molecules or groups of molecules which have affine properties for other substances. These include, in particular, enzymes and substrates interacting with enzymes. On the one hand, the substrate or, on the other hand, the enzyme as a reactive component on the second Component arranged The same applies with antibodies / antigen, Biotm / Streptavidm systems Strep tavidm or biotin as a specific reaction component firmly bound to the dye has the advantage that the dye can be used universally as a reaction partner for biotinylated or streptavidin-linked components. These in turn can have very different functions, for example, again specifically against another component or act as a catalyst. Also nucleic acids of the RNA or DNA type can be used as reactive components in the sense of the carrier according to the invention. The nucleic acids are able to react with the corresponding ones to hybridize complementary or partially complementary strands, depending on the stringency of the reaction conditions, and to form stable complexes. It is therefore possible to identify specific strands of nucleic acid in a sample to be examined and to process them further on the basis thereof. Combinations of the reactive components can also be arranged on or on the second component. Carriers according to the invention are then obtained which can be used for various problems

By choosing the crosslinking agent and its concentration and setting certain process conditions, the crosslinking reaction can be controlled so that the second component envelops the first component quasi in a molecular network, the mesh of which has a narrow mesh size distribution

With the process conditions of the crosslinking, the number of free binding sites on the particle surface can be set, which remains free by binding the least bifunctional crosslinker with only one function to the surface for further binding, in particular of reactive components. The number of binding sites that are created can be full or, after partial saturation, to a defined extent

In particular, the thickness of the shell can be determined by the process conditions, the homogeneous valley of which still leaves can be improved by a fractionation. A multi-stage process of the coating can further improve the inclusion of the first component.

The first component of the particle according to the invention preferably has at least one detectable property which, at least in its quality, is not inherent in component 2 and / or the reactive components bonded to it, such as absorption or emissivity of electromagnetic waves, mass, magnetism, dielectric. Radioactivity, high and _/ or density on detectable properties, which can have the core as the first component of the carrier according to the invention, is also understood to mean a pharmacological-biological effect and a catalytic effect or combinations thereof. For example, the absorption or emission capability can be electromagnetic Waves are produced by appropriate chromophores or fluorophores. The properties of mass, size and density are physically related and can be adjusted accordingly, for example by specifically heavy particles. The property size can be advantageous for the Using agglomeration and the property mass for gravimetry The agglomeration is advantageous for the specific precipitation of components in solutions or microemulsions. The first component can be provided with the property radioactivity by radioactively marked structures. The other properties mentioned can be similarly done with the first component connect The first component can also be a capsule and contain liquids or particles that are not sufficiently enveloped (eg extremely small or unstable in solution)

In an advantageous embodiment of the carrier according to the invention, the carrier is designed such that the first and second components are separably connected to one another. The connection between the first and second components is made by wrapping the first component with the second principle. It is possible to remove the second component to expose the most iconic component, possibly for a mechanical engineering The properties associated with the core are easier to remove. In the case of proteins, for example, the second component can be removed by appropriate proteolytic enzymes. This degrades the shell so that the core remains. This can then be treated further according to its property to be measured. It is also possible to detach the core from the dressing of the first / second component by treatment with a medium in which the core is preferred, so that ultimately an "empty" shell remains, or to dissolve the entire particle with a total solvent For example, if a dye that is soluble in ethanol is enveloped by the second component, it can be treated with the solvent and the ethanolic solution obtained can be measured spectroscopically. If the conditions are standardized and calibrated, a corresponding discoloration can be used as a measure be used for quantitative determinations

In addition to the individual, storage-stable, particle-shaped carriers, their appearance is also of great importance when carrying out application processes. The storage-stable, particle-shaped carriers appear in a plurality of populations in appearance. For an application of the particles according to the invention it is preferred that the carriers are present in populations which are characterized by a narrow distribution of the size of the individual carrier particles according to the invention

It is particularly preferred that the population has carrier particles which have both a narrow range of the size distribution of the shell and a narrow range of the size distribution of the core and thus a narrow distribution of the size ratio shell / core. A homogeneous distribution, e.g. the color intensity or the magnetizability, desired for the core in particular for the entire particle

For the practical use of the particle aL carrier according to the invention, it is advantageous to use a or the second form component to arrange a high concentration of reactive components. As a result, relatively high binding constants for corresponding complementary structures can be achieved, for example, in immunoassays, although the individual reactive component may have only an average binding constant for the corresponding complementary structure. However, due to the large number of binding sites, increasing the number of binding sites the effectiveness of education (avidity) is reached

A method for producing the carrier according to the invention comprises the steps of reacting the first component at least once with a crosslinkable polymer. The polymer can be physically adsorbed on the surface of the first component. The crosslinkable polymer will form the second component after further treatment steps treatment with crosslinking agent as crosslinking agent, in particular, bifunctional molecules such as glutardialdehyde, dicarboxylic acids, acrylates, methacrylates are suitable. Crosslinking agents carrying the olefinic groups can be activated, for example, by photoreactions or other radical chain reactions network

If necessary, the first component can be subjected to a separation according to size and / or another property before the treatment and / or the intermediate product with the second component and / or the particle in order to achieve a distribution of the size and / or another property that is as homogeneous as possible The treatment of the first component with polymers is preferably carried out two to three times and particularly preferably a separation according to size

The method is particularly advantageous since, regardless of the reaction, the first component is first homogenized and its concentration in the suspension is adjusted 1 af t Depending on the first component used, SMII are common Use method to homogenize and stabilize the suspension. The second component is preferably used to stabilize the suspension if it is a polar compound with sufficiently good adsorption on the first component. The ratio of the concentrations of the first and second components is chosen so that a suitable shell thickness is achieved by adsorption In the multi-stage process, the shell thickness is chosen to be rather thin. Other parameters such as time and temperature can also be used to influence the adsorption. Then the intermediate product can be homogenized again in order to achieve good crosslinking of the shell, in particular in the inner region near the first component calibration, the crosslinking component is then used in a crossover of several orders of magnitude. The effect of the crosslinking component can also be influenced by other parameters, in particular the exposure time, just like the number of reactive groups formed on the surface by one-sided g bound crosslinker molecules, which can subsequently be reduced by partial blocking

The carriers according to the invention are preferably used in assay methods such as immunoassay, solid-phase assays and / or chromatographic assay. They can also be used as vehicles for the transport of active substances if the first component, for example, is enveloped by the second component and the second component, for example Afmatate transport means, for example, transport of pharmacologically active substances by means of antibodies which are arranged on the second component and bind specifically to a specific target structure

Particles with a radioactive nucleus can also be used advantageously because they act or are concentrated mainly at the place of use due to the transport of the afflicate and therefore overall lower amounts of radioactivity can be used, so that a systemic load can be kept within narrow limits The use of the storage-stable, particle-shaped supports according to the invention as a catalyst for chemical reactions is also advantageous. Thus, a magnetic core can be used for rapid mixing of the carrier-bound catalyst (biocatalyst) with the reaction solution, the weight of which then ensures rapid segregation

The invention is illustrated by the following examples]

example 1

Production of a Sudan IV dye particle with a high loading of streptavidin as a specific reactive component for biotmy lated components

1 peptization

10.0 g of Sudan IV were added to 100 ml of PBS buffer (Phosphate Buffer Solution) with 2% BSA (Bovine Serum Albumin, sterile-filtered over 2 μm) and stirred at high speed to a homogeneous suspension. The suspension was then coarsely filtered (filter paper BioRad model 543)

The suspension was divided into two centrifuge tubes and centrifuged in a centrifuge precooled to 4 ° C. for 5 minutes at 1000 rpm, at 2000 rpm and at 3000 rpm, followed by a second filtration.

2 Networking and activation.

50 ml of 50% aqueous ιge Glutaraldehydlosung were placed on tur Raumtempera¬ (hood) and adjusted with about 11 ml of 0.3 M Na ₂ HPO _ι buffer at pH 7.3 (check with pH meter) Then, 25 ml of PBS were Buffer and 5 ml of a 1 liter mixture of PBS buffer and bidistle II π added. The entire solution (pH 7.3) was sterilized (0.2 μm) 20 ml of the peptized Sudan IV suspension were added to each 20 ml of this glutaraldehyde buffer solution with vortexing (vortex) (4 parallel batches) (approx. 1.5 M glutaraldehyde or 2.8 M aldehyde groups in the reaction solution, approx. 5xl0 ^"4 M BSA or at approx. 300 amino acids per BSA approx. 4.5x10" M reactive amino acid, ie approx. 60 aldehyde groups per amino group) and shaken for 4 hours at room temperature

In each case 40 ml of activated suspension was stabilized in the centrifuge tube with 2.2 ml of 2% BSA solution (0.2 μm filtered). The batches were then centrifuged at 2500 rpm for 5 minutes and then coarsely filtered

3 column cleaning (gel filtration)

A column with CL-4B-Sepharose (Pharmacia) was regenerated well and equilibrated with PBS buffer at least for one hour at room temperature, then the round filter was applied and the excess buffer volume was suctioned off or drained off. The 160 ml of the stabilized suspension were applied to the column and covered the column. After the infiltration (approx. 25 minutes), the column edges were rinsed with PBS buffer and a pump started

Conical 12 ml tubes with line markings for the collection volumes were prepared for the fractionation.

Tubes No. 1-10 and 23-30 each 4 ml; No. 11 and 22 4.5 ml, No. 12 and 21 5 ml; No. 13 and 20 5.5 ml; No. 14-19 6 ml

As soon as the red running front appeared in the outlet, the fractions were collected. The gel filtration took about 30 minutes

Each 5 μl of each fraction was diluted (1 1000) with 5 ml PBS buffer for each optical-visual color strength assessment and vortexed for 5 seconds (Vorfex). The evaluation of the fractions according to their color strength led to a broad central peak area with high color strength and clearly falling color in the fractions before and after. The broad peak area of approx. 140 ml was used. Its fractions were pooled, distributed into 3 50 ml tubes, centrifuged for 5 minutes at 2500 rpm and then coarsely filtered

(Steps 2 and 3 were repeated one or more times if needed for a thicker and / or more secure shell)

4 Conjugation with streptavidm as a specific reactive component

100 mg streptavidm were dissolved in 6 ml PBS buffer, for quality control the protein concentration was determined with the optical density at 280 nm and compared with the manufacturer's specification. The streptavid solution was placed in a 6 mm dialysis tube and at 4 ° C. overnight against 1 1 PBS buffer dialyzed The solution was placed in a tube, the tube was rinsed with 4 ml PBS buffer, and the protein concentration was checked again with the 0Dπ _{O (} to check the concentration). The streptavid solutions were centrifuged for 5 minutes at 4000 rpm and the Supernatant for conjugation is used after determining the 0D _{2ÖC again}

The coarsely filtered suspension of the Sudan IV dye coated with crosslinked BSA with active residual aldehyde groups was coupled in 4 batches with the streptavid supernatant as follows

Approx. 3 ml of streptavid solution (with approx. 11 mg / ml protein) were placed in a 50 ml tube. About 30 ml of the suspension were added with swirling (ie approx. 33 mg streptavidm per 33 ml suspension). The solutions were left overnight in the room Leave the temperature in the overhead shaker and centrifuged the next morning at 2500 rpm for 5 minutes and then coarsely filtered. The total suspension volume was then cd 130 ml

1 column cleaning CL 6B-Sepharosc color test The column was prepared and equilibrated as under 3. The infiltration of the 130 ml suspension lasted approx. 25 minutes, the gel filtration approx. 30 minutes. Fraction tubes were prepared as under 3. The fractions were either diluted as under 3 and only assessed visually and visually the color quality of the fractions was tested in a dilution of 1 50 in a test in accordance with DE AI-195 00 862, Example 1, for their usability. 250 were placed on a column with a gel bed with monoclonal mouse anti-human IgG antibody μl of a 1 5000 diluted pooled serum sample with originally 8 4 lU / ml human anti-tetanus IgG (sensitivity 1.7 mlU / ml, absolutely approx. 0.4 mlU, international units), followed by 250 μl of a solution of 5 μg / ml biotmylier learn fetanus toxoid After 250 μl of the 1 50 diluted suspension of the dye coupled with streptavidm had been applied, a clear coloration should still be discernible. The central g epool t <^ - area with high absorption encompassed a broad peak area of approx. 100 ml, for less demanding the two shoulder areas on the left and right of approx. 10 ml each were pooled. After vortexing and coarse filtration, both pools were used up to Stabilization stored at 4 ° C (possibly overnight)

6 stabilization

20% BSA solution in PBS buffer was sterile filtered to 0.2 μm. In 50 ml tubes which had been rinsed with BSA solution, 18 ml of the coarsely filtered suspension had become 22 ml of 20% BSA solution with vortexing The suspensions were then coarsely refilled

7 storage

In tightly sealed 50 ml tubules is the suspension εtabi- lι ^c t ICI with 0.09% Natnumazid, at 4 ° C for at least 12 months, ^"" Unstable with tabilem Abεoiptionswert 8. Properties

Compared to an average size of approx. 50 nm of the Sudan IV particles, the size after approx. One coating is approx. 51 to 200 nm, after a second coating at 300 to 400 nm

Example 2

Immunoassay with the storage-stable, particle-homogeneous Tiagermaterialien according to Example 1

Semi-quantitative and quantitative measurement of the tetanus vaccination status, i.e. the concentration of anti-tetanus IgG in blood

a) Semi-quantitative test

For the semi-quantitative test for visual impact, a reaction column for simultaneous multiple measurement according to DE-Al-195 009 862 with 3 fields was used

The lower reaction field (comparison field) of the reaction column is loaded with protein G and bound to it a defined amount of anti-tetanus human IgG, which corresponds to adequate vaccination protection m IU (International Units) of the blood amount m of the capillaries for the blood application Serum diluted accordingly and the entire human IgG including the tetanus-specific bound in flow to the protein G of this reaction field (protein G coupled to CNBi - activated agarose, see DE-A-195 00 862, example 2 there)

The middle negative control field contains CNBr-activated Sepha rose 4b with covalently coupled BSA An upper reaction field (test field) of the reaction unit contains only protein G coupled to CNBr-activated agarose

A defined amount of blood is applied to the column with a capillary. After washing with washing buffer, 250 μl of a solution of 5 μg / m] of biotinylated tetanase toxoid (degree of breadmylation 50) are applied in washing buffer. After washing again, a 1 20 -washing buffer dilution of the streptavidm dye emulsion is applied applied and washed again

The entire human IgG of the sample is bound in the test carrier bed during its passage. In both fields in the test field and in the comparison field, a corresponding amount of biotmylieitetetanus toxoid is bound during the passage of the previously bound anti-tetanus human IgG. Unspecifically bound proteins are released from the The subsequent puff is washed out. Then, during the passage of the dye emulsion in the test field and in the comparison field, the amount of streptavid-coupled dye corresponding to the amount of tetanus toxoid bound is also bound. Here, too, unspecific bound protein is washed out by the washing buffer. Nothing is washed in the negative control field bound

The semi-quantitative evaluation is carried out by visual color comparison. If the color of the test field is the same or stronger than that of the comparison field, the vaccination status is sufficient. If it is below this, vaccination should be carried out, and the greater the difference in color, the more urgent it is (fine subdivisions of comparison fields) , eg two years of protection, after five years of protection, vaccination recommended, vaccination strongly recommended, can be prepared according to medical or WHO information. Eme alternative is the evaluation of the depth of penetration of the colors into the test field with appropriate markings. Then a comparison point d can be omitted or serve as protection)

\ jι Quantitative test A test field is not required for this, but positive and negative control fields can be built in for safety

The field is loaded with mouse anti human IgG in accordance with DE-A-195 00 862, Example 2. The application sequence and the reactions smd as described below a) The evaluation is carried out by photometric absorption measurement at 520 nm or 492 nm after elution with alcoholic alcohol Solution

Elution with alcohol is necessary because, owing to the high number of binding sites, the dye marker sits on the gel bed with such stability that it cannot be detached from the gel bed like other markers with the aid of pH changes or by displacement with a competition molecule. also not partially, but in this case only by means of a resolution

The test sensitivity for both evaluations is in the mlU / ml range for anti-tetanus-human IgG Absolutely, further test optimization amounts below 10 pg IgG can be determined qualitatively (visually) and quantitatively, even less when enriched with the column (pg / ml Area) The ongoing quality control showed that the emulsion remained stable for at least 1 .. months

Example 3

Synthesis of activated dye particles

0.1 to 2 g of carbon are added to 20 ml of BSA solution in a concentration range of 1 to 50 mg / ml in 0.01-0.2 M phosphate buffer solution, pH 6-8.5. The mixture is placed on a magnetic stirrer or a Vortex mixer mixed until the protein is adequately adsorbed (peptized). The suspension obtained is centrifuged at 6000x g for 5 to 10 minutes The carbon particles from 50 to 350 nm on which BSA is adsorbed are activated in the next step with glutardialdehyde. The glutardialdehyde concentration for this is in the range of 1 to 25%, the activation time is 20 to 120 minutes.

The activated suspension is purified by centrifuging 3 to 4 times and by gel filtration with Sepharose 6B, 4B, 2B, CL-6B, CL-4B, CL-2B Sepharcryl S300 or with other gels (Toyoperl, Ultragel etc.) , the exclusion limit must not be less than 1 million Daltons for globular proteins. With this method, black dye particles are obtained. The production of other dye particles takes place analogously, with instead of carbon e.g. Sudan II is used for red, Sudan III for dark red, Sudan-black for gray, Tetiazolformazanvrolett for violet, Neotetrozoldiformazan for dark violet and Tetrazoldiformazan blue for blue. The working range for these conjugates in suspension is 0.08% based on the dry weight. The dye labels are produced by conjugation with anti-analytes such as protein A, streptavidin or antibodies.

Example 4

Serological determination of anti-HIV antibodies on a non-porous solid phase using a protein A-carbon conjugate.

Polystyrene ELISA plates with adsorbed synthetic peptides of HIV-1 and HIV-2 were used as the solid phase. A Kanmchen anti-HIV serum was then added in a dilution series. After an incubation of 15 minutes and a washing step, protein A-carbon conjugate was added and the result spot was read after 15 minutes after a washing step.

Analogous experiments were carried out in parallel with commercially available Protein A gold colloid (40 nm particle size) and Protein A POD. The comparison of the visual evaluation showed a sensitivity of the other two markers for a dilution of 1/1280, for the carbon conjugate of 1/20480

Example 5

Determination of HCG with carbon conjugate with thin layer chromatography

A strip of 2x16 mm nitrocellulose is glued to transparent PVC 0.5 mm. The end of the strip was glued with a 1 x 1 cm piece of chromatography paper as a suction element. A solution of anti-HCG was used in the middle of the nitrocellulose strip with a Hamilton syringe. Antibody (1 mg / ml in phosphate buffer) added. After 30 minutes, blocking with 1% case solution (phosphate buffer with Tween) (hour), then washing and drying

The HCG standard is diluted once in phosphate / Tween puffer, then again in urine from healthy people, with up to 0.1% Tween 20 being added to 50 μl of this standard solution, 50 μl carbon conjugate with anti HCG added The free end of the strip is immersed in this solution, after 2 to 3 minutes the result is visually read as a black line. The sensitivity of 50 mlU / ml is sufficient for a pregnancy test after one week

Claims

Expectations

1 Storage-stable particle consisting of at least one first and at least one second component, the second component comprising at least one crosslinkable polymer as a shell at least partially enveloping and / or enveloping the first component as a core and the first component having at least one detectable property , obtainable by reacting a first component with the crosslinkable polymer and then reacting the product formed with a crosslinking agent, so that the first component remains stable in storage in the second component.

2. Particle according to claim 1, characterized in that the particle is a storage-stable carrier for carrier-bound reactions, detection and / or isolation methods, the carrier being suitable to be provided with at least one Reaktivkom¬ component, in particular a specific reactive component.

3. Particle according to claim 1 and / or 2, characterized gekennzeich¬ net that the first component is em-like or enveloped by the second component.

4. Particles according to at least one of claims 1 to 3, characterized in that the second component is at least one polymer which has active or activatable functional groups. Particles according to claim 3, characterized in that at least one polymer is formed from one or more crosslinkable polymers and / or crosslinkable monomers

Particles according to at least one of claims 1 to 5, characterized in that the polymer is formed from at least one polyamide, preferably a protein, or at least one other biopolymer with functional groups

Particles according to mmdeεtens one of claims 1 to 6, characterized in that the second component can be crosslinked with at least bifunctional compounds

Particles according to claim 7, characterized in that at least bound bifunctional compounds bound to the surface still have at least one reactive group, and that these reactive groups can be saturated in whole or in part and / or in whole or in part, preferably to a certain extent , can be used for the covalent bonding of reactive components or a further layer of the second component

Carrier according to at least one of claims 2 to 8, characterized in that the reactive component is a molecule or a group of molecules with affine properties for other substances

Carrier according to claim 7, characterized in that at least one reactive component is an enzyme, a substrate interacting with enzymes, an antibody, antigens, biotin or streptavidm, a nucleic acid of the RNA or DNA type, which can be hybridized with another nucleic acid Particles according to at least one of Claims 1 to 10, characterized in that the second component envelops the first component in a molecular network whose meshes have a narrow mesh size distribution

Particle according to at least one of claims 1 to 11, characterized in that the detectable properties of the first component is at least one from the list of absorption or emission capability of electromagnetic waves, mass, magnetism, dielectric, radioactivity, size, density and pharmacological, biological and / or catalytic effect

Particles according to at least one of claims 1 to 12, characterized in that the first and second components are separably connected to one another

Particles according to at least one of claims 1 to 13, characterized in that the carrier is present in populations and the populations according to the size of the particle after the coating and / or according to a detectable property of the first component before, during and / or after the coating are fractionated at least once

Particle according to claim 14, characterized in that the particle is present in a population with a narrow distribution of the size and / or the detectable property, in particular the size and / or color

Particle according to claim 14 and / or 15, characterized in that the particle lies within a narrow range for the distribution of a detectable property of the first component, in particular the size and / or the color Particles according to at least one of claims 2 to 16, characterized in that the carrier has a high occupancy of the second component with at least one reactive component, preferably specific reactive components

Particles according to at least one of claims 1 to 17, characterized in that the reactive component (s) is linked to the shell and the core via spacers

to produce a particle from at least one first and at least one second component, the first component being treated at least once with at least one crosslinkable polymer as the second component and the respective product and / or the end product with at least one at least bifunctional compound is networked

Method according to claim 19, characterized in that in the method a fractionation of the untreated first component, an intermediate product and / or the particle is carried out at least once according to the large and / or another detectable result

A method according to claim 19 and / or 20, wherein the at least bifunctional compound is a compound such as, for example, a dialdehyde, in particular glutardialdehyde, a dicarboxylic acid, an acrylate or a divmyl compound, and the crosslinkable polymer via condensation, addition or substitution reactions is networked

Process according to at least one of Claims 19 to 21, characterized in that the treatment with the polymer and / or the crosslinking agent and / or a fractionation is carried out twice or several times 23. Use of the particle according to at least one of claims 2 to 18 in assay methods, in particular qualitative, semi-quantitative and quantitative column solid phase immunoassays.

24 Use of the particle according to claim 23, characterized gekenn¬ characterized in that the ascertainable property is evaluated qualitatively manually and / or visually, or semi-quantitatively by means of comparison and / or concentration zones

25 Use of the particle according to claim 23, characterized in that the detectable property is quantitatively evaluated by measurement, if necessary after the second component and / or the entire particle has been chlorinated in another solvent or under other conditions such as a different pH and / or others Salt concentrateICH

26 Use of the particle according to at least one of claims 23 to 25, characterized in that at least two detectable properties are used, for example magnetism to improve the mixing and / or the separation of the solid phase from the fluid phase and / or absorption for quantification .

27 Use of a particle according to at least one of claims 1 to 15 for the use of pharmacologically and / or biologically active substances, characterized by a dissolution or separation of at least one of the second component.

28 Use of the particle according to claim 2 ^~>, gekenn¬ characterized characterized that a narrow size distribution of the second component there are suitable the time to dissolution and / or a narrow distribution of at least one detectable property of the first component determines the action within a narrow range Use of a particle according to claim 27 and / or 28 as a vehicle for the transport of affitates of active substances

Use of a particle according to at least one of claims 2 to 15 as a catalyst for chemical and / or biochemical reactions.

Use of the particle according to claim 30, characterized in that at least two detectable properties are used, for example magnetism for rapid mixing and weight for rapid separation